List of Excipients in Branded Drug PHENTERMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	PHENTERMINE AND TOPIRAMATE	phentermine and topiramate	66993-780	CELLULOSE, MICROCRYSTALLINE
Prasco Laboratories	PHENTERMINE AND TOPIRAMATE	phentermine and topiramate	66993-780	ETHYLCELLULOSE
Prasco Laboratories	PHENTERMINE AND TOPIRAMATE	phentermine and topiramate	66993-780	FD&C BLUE NO. 1

Generic Drugs Containing PHENTERMINE

Company	Ingredient	NDC	Excipient
Aurolife Pharma LLC	phentermine hydrochloride	13107-105	AMMONIA
Aurolife Pharma LLC	phentermine hydrochloride	13107-105	BUTYL ALCOHOL
Aurolife Pharma LLC	phentermine hydrochloride	13107-105	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in PHENTERMINE?

# Of NDCs	Excipient
3	AMMONIA
3	BUTYL ALCOHOL
1	CELLULOSE, MICROCRYSTALLINE

Phentermine Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 12, 2026

Phentermine is a mature, genericized sympathomimetic amine with limited active-ingredient patent protection in the United States. The strongest commercial opportunities are in differentiated oral dosage forms, dose flexibility, taste masking, adherence, supply-chain reliability, and combination products rather than in a new chemical entity. Excipient selection must account for low-dose content uniformity, controlled-substance handling, obesity-population comorbidities, and FDA requirements for inactive ingredients.

What is the FDA status of phentermine?

Phentermine is FDA-approved for short-term use as an adjunct to caloric restriction and exercise in patients with obesity. It is marketed primarily as phentermine hydrochloride in tablets, capsules, and low-dose tablets. The drug is a Schedule IV controlled substance under the federal Controlled Substances Act. [1,2]

Attribute	Phentermine
Active ingredient	Phentermine hydrochloride or phentermine resin, depending on product
Therapeutic class	Sympathomimetic amine anorectic
Main indication	Short-term obesity management
Common strengths	8 mg, 15 mg, 30 mg, 37.5 mg
Dosage forms	Tablets, capsules, low-dose tablets
FDA pathway	Abbreviated New Drug Application for generics; 505(b)(2) possible for differentiated products
Controlled-substance schedule	Schedule IV
Reference products	Adipex-P, Lomaira and other approved products
Primary regulatory constraints	Abuse potential, cardiovascular effects, labeling, content uniformity, bioequivalence

Adipex-P is available in 37.5 mg tablets and capsules. Lomaira is a lower-dose 8 mg tablet intended for administration before meals and, in labeling, may be used multiple times daily. [3,4] Product-specific inactive ingredients differ and must be checked against the current FDA labeling and inactive ingredient database.

Phentermine is not a chronic obesity therapy in the same regulatory position as semaglutide, tirzepatide, or liraglutide. Commercial positioning therefore depends on low cost, rapid availability, dose flexibility, and convenience rather than long-term disease-management claims.

What patents protect phentermine products?

The original phentermine active-ingredient and basic dosage-form inventions are old and generally do not create a meaningful blocking patent position for ordinary generic phentermine hydrochloride tablets or capsules in the United States.

Patent estate for single-agent phentermine

The practical patent position is:

Asset category	Commercial relevance
Original compound patents	Generally expired or commercially irrelevant
Conventional immediate-release tablets	Usually available through generic competition
Conventional capsules	Usually available through generic competition
Low-dose 8 mg tablets	Potential room for formulation differentiation, but not necessarily patent-protected
Taste-masked dosage forms	Possible 505(b)(2) or formulation-patent opportunity
Extended-release products	Potentially protectable if clinically and technically differentiated
Combination products	May have separate patent estates
Manufacturing processes	Potential trade-secret value; patent value depends on process novelty

An applicant should review the current FDA Orange Book by product and applicant before filing, especially for any listed patents attached to branded phentermine products or combination products. The Orange Book is the controlling public source for listed patents and exclusivity associated with approved drug products. [5]

Are there Paragraph IV challenges for phentermine?

Paragraph IV litigation is less likely for standard phentermine hydrochloride tablets because many products are already generic and the core product is mature. A Paragraph IV strategy becomes more relevant when targeting:

• A branded low-dose product with a listed formulation patent.
• A novel extended-release formulation.
• A taste-masked or orally disintegrating product.
• A fixed-dose phentermine combination.
• A product with a device, multiparticulate, or modified-release delivery system.

The relevant commercial question is not whether phentermine has patents in the abstract. It is whether the specific reference product has Orange Book-listed patents that could delay approval or expose the applicant to a 30-month stay following a Paragraph IV notice.

Do combination products create separate patent risk?

Yes. Qsymia combines phentermine with topiramate extended release and has a separate regulatory and patent history from single-agent phentermine. A company developing a phentermine/topiramate product must conduct a product-specific Orange Book review and assess patents covering the combination, release profile, manufacturing process, and dosing regimen. [6]

A single-agent phentermine applicant cannot assume that combination-product patents block the single-agent market. The reverse is also true: freedom to operate for phentermine hydrochloride does not establish freedom to operate for phentermine/topiramate.

What excipients are used in phentermine formulations?

Immediate-release phentermine products typically use conventional tablet or capsule excipients. The formulation objective is dose accuracy, mechanical strength, rapid dissolution, stability, and manufacturability.

Potential excipient classes include:

Formulation function	Candidate excipient classes	Strategic considerations
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate, mannitol	Select based on dose uniformity, compressibility, moisture sensitivity and patient tolerability
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Avoid over-binding that slows disintegration
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid release and robust dissolution
Lubricant	Magnesium stearate, sodium stearyl fumarate	Excess lubricant can impair wetting and dissolution
Glidant	Colloidal silicon dioxide	Supports powder flow and low-dose uniformity
Film former	Hypromellose, polyvinyl alcohol	Enables color, branding and moisture protection
Opacifier	Titanium dioxide or alternative permitted opacifiers	Assess jurisdiction-specific requirements
Sweetener	Sucralose, saccharin sodium, mannitol, xylitol	Relevant to chewable or orally disintegrating products
Flavor	Mint, vanilla, citrus or proprietary flavors	Requires taste-masking and stability evaluation
Controlled-release matrix	Hypromellose, ethylcellulose, methacrylate copolymers	Creates formulation differentiation but increases development and bioequivalence risk

All excipients must be acceptable for the intended route, dosage form, strength, and daily exposure. FDA’s Inactive Ingredient Database is a starting point, not a substitute for a complete regulatory assessment. [7]

What excipient strategy best fits immediate-release phentermine?

The lowest-risk strategy is a conventional immediate-release tablet or capsule using established, compendial excipients already used in oral solid dosage forms.

Low-dose content uniformity

Low-dose phentermine products create a formulation risk because the active ingredient may represent a small fraction of total tablet weight. The blend must maintain uniform distribution during mixing, transfer, compression, and encapsulation.

Preferred controls include:

1. Particle-size engineering for the active ingredient and major diluent.
2. Geometric dilution during preblending.
3. Use of a carrier such as microcrystalline cellulose or mannitol.
4. Low-shear transfer systems that reduce segregation.
5. Blend uniformity and content-uniformity testing.
6. In-process weight control and tablet hardness monitoring.

A direct-compression platform can reduce processing steps, but it requires reliable powder flow and segregation control. Wet granulation may improve uniformity and compressibility but introduces moisture, drying, and stability risks.

Dissolution and disintegration

A standard immediate-release product should target rapid and reproducible dissolution across the approved pH range. Crospovidone or croscarmellose sodium can support fast disintegration. Excess hydrophobic lubricant, especially magnesium stearate, can reduce wettability and delay dissolution if mixing time or concentration is poorly controlled.

For an ANDA, the safest approach is usually a formulation that matches the reference product’s release profile without unnecessary excipient novelty. A novel excipient system may create a differentiated profile, but it also increases the burden of formulation justification and bioequivalence development.

Capsule versus tablet

Capsules offer flexible fill weights, easier color differentiation and potential compatibility with multiparticulates. Tablets offer lower packaging cost, stronger unit-dose identity and better suitability for scored or low-dose products.

A capsule can support a modified-release bead platform, but this may trigger more complex dissolution, stability and bioequivalence requirements. A tablet is usually the more efficient platform for a conventional generic or low-cost branded generic.

What formulation patents could protect a new phentermine product?

Patentable differentiation is more plausible in the dosage form than in the active ingredient.

Orally disintegrating and chewable products

An orally disintegrating tablet could target patients who have difficulty swallowing, need discreet administration, or prefer administration without water. Commercial value depends on:

• Rapid disintegration.
• Acceptable taste.
• Low friability.
• Adequate mechanical strength.
• Moisture-resistant packaging.
• Stable flavor and sweetener system.

Phentermine has a bitter or unpleasant taste profile that may require ion-exchange resins, polymeric coating, pH-modifying agents, cyclodextrins, or multiparticulate coating. A true taste-masking technology can support formulation patents if it produces a measurable technical effect and is not an obvious adaptation of known systems.

Extended-release products

An extended-release phentermine product could support once-daily dosing and reduce peak-related adverse effects. The development risk is higher because the product must establish a clinically acceptable exposure profile and demonstrate bioequivalence or therapeutic equivalence through the applicable FDA pathway.

Potential platforms include:

• Hydrophilic matrix tablets.
• Insoluble polymer matrices.
• Coated multiparticulates.
• Ion-exchange resin complexes.
• Osmotic or membrane-controlled systems.

The commercial opportunity is strongest if the product can offer a meaningful dosing or tolerability advantage without requiring a new efficacy claim unsupported by clinical data.

Abuse-deterrent or tamper-resistant formulations

Because phentermine is Schedule IV, abuse-deterrent positioning may have value. The regulatory and commercial payoff is uncertain because the product is not in the same abuse-risk category as Schedule II opioids. A company would need to demonstrate that the technology addresses a relevant manipulation route and justify the associated price premium.

Fixed-dose combinations

Combination products are commercially more defensible than ordinary phentermine tablets, but they carry higher regulatory and patent risk. Possible categories include combinations with other weight-management agents, though safety, cardiovascular effects, drug interactions, and labeling would require careful evaluation.

Qsymia demonstrates the commercial and regulatory complexity of combining phentermine with another active ingredient. [6] A follow-on developer must assess separate patents, clinical justification, dose-ratio selection, and any abuse or pregnancy-related warnings associated with the partner drug.

How does phentermine compare with newer obesity drugs?

Phentermine competes on price and accessibility, not on chronic-treatment positioning.

Product category	Typical commercial advantage	Main disadvantage versus phentermine
Generic phentermine	Low acquisition cost and broad availability	Short-term labeling and sympathomimetic safety concerns
Phentermine/topiramate ER	Once-daily combination therapy	Higher regulatory complexity and combination-product patent risk
GLP-1 receptor agonists	Chronic-treatment positioning and substantial weight-loss efficacy	High cost, injection or specialized delivery, supply constraints
Dual or triple incretin therapies	Strong efficacy and premium pricing	High development cost and complex reimbursement
Orlistat	Non-stimulant mechanism	Gastrointestinal tolerability and lower perceived convenience
Naltrexone/bupropion	Non-sympathomimetic combination option	Contraindications and central nervous system tolerability issues

Phentermine can remain commercially relevant as a low-cost entry therapy, particularly where payer coverage for newer incretin products is limited. A branded-generic strategy should emphasize dose options, reliable supply, packaging, and prescriber familiarity.

What commercial opportunities exist for phentermine?

Opportunity 1: Low-cost branded generic

A company can differentiate a conventional product through:

• Stable supply.
• Consistent tablet appearance.
• Blister packaging.
• Serialization and controlled-substance inventory controls.
• Multiple strengths.
• Pharmacy-channel reliability.
• Contract manufacturing capacity.

The product would face substantial price competition. Scale, manufacturing yield, and distribution efficiency are more important than a premium formulation story.

Opportunity 2: Low-dose adherence product

An 8 mg or similarly low-dose product can support divided dosing and titration. A company could pursue a branded-generic strategy around:

• Scored tablets.
• Small tablet size.
• Clear strength differentiation.
• Unit-dose blister packs.
• Calendar packaging.
• Patient instructions aligned with approved labeling.

The regulatory claim must remain within the approved label. Marketing cannot convert a short-term obesity indication into an unsupported chronic-use claim.

Opportunity 3: Taste-masked orally disintegrating product

This is the strongest formulation-led opportunity if the product delivers a clear patient benefit. The target users would include patients who have difficulty swallowing tablets and patients seeking discreet administration.

The main development risks are:

• Bitter taste breakthrough.
• Moisture sensitivity.
• Tablet friability.
• Inconsistent disintegration at different humidity levels.
• Higher packaging cost.
• Need for a robust bioequivalence strategy.

Opportunity 4: Modified-release phentermine

An extended-release product could create a higher-value product profile, but the development program would be materially more expensive than a standard ANDA. Exposure, peak concentration, adverse events, food effect and dose proportionality would require careful study.

This strategy is more suitable for a 505(b)(2) program or a product supported by a clearly differentiated reference and clinical rationale than for a conventional generic submission.

Opportunity 5: Manufacturing and supply-chain control

Phentermine’s controlled-substance status creates operational barriers that can become commercial advantages. A reliable supplier must manage:

• Quota and controlled-substance ordering requirements.
• Secure storage.
• Inventory reconciliation.
• Theft and diversion controls.
• DEA registration and reporting.
• Forecast accuracy.
• API supplier qualification.

A company with compliant controlled-substance infrastructure can gain share even without a novel excipient system.

What FDA and controlled-substance issues affect commercialization?

The product must comply with FDA drug-application requirements and federal controlled-substance rules. Key issues include:

• Appropriate ANDA or 505(b)(2) pathway selection.
• Bioequivalence to the designated reference product.
• Inactive-ingredient acceptability.
• Content uniformity for low-dose strengths.
• Dissolution across relevant conditions.
• Stability under proposed packaging.
• Schedule IV security and recordkeeping.
• Labeling consistent with short-term-use restrictions.
• Advertising that avoids unsupported chronic-use or superiority claims.

A new dosage form may require a stronger clinical and pharmacokinetic package than a conventional generic. Excipient changes that affect absorption, dissolution, taste, or release can become regulatory issues even when the active ingredient is unchanged.

How strong is the patent estate for phentermine?

The patent estate for conventional single-agent phentermine is weak from a blocking perspective but potentially useful for new formulations.

Strategy	Patent strength	Regulatory burden	Commercial attractiveness
Conventional IR tablet	Low	Low to moderate	Moderate at scale
Conventional capsule	Low	Low to moderate	Moderate
Low-dose scored tablet	Low to moderate	Moderate	Moderate
Orally disintegrating tablet	Moderate	Moderate to high	Moderate to high
Taste-masked product	Moderate to strong if technically differentiated	Moderate to high	High if patient benefit is clear
Extended-release product	Moderate to strong	High	Moderate to high
Phentermine combination	Potentially strong	High	High but competitive
New manufacturing process	Variable	Moderate	Depends on cost advantage

A formulation patent should claim a measurable technical structure or result, such as a defined release profile, taste-masking performance, stability improvement, particle-size distribution, or manufacturing process. Broad claims covering ordinary excipient substitutions are vulnerable to validity challenges and design-around strategies.

What generic launch scenarios exist?

Scenario 1: Standard generic launch

This is the fastest and lowest-risk path. The applicant launches an immediate-release tablet or capsule after ANDA approval and competes primarily on price and supply reliability. Margins are likely to compress as additional manufacturers enter.

Scenario 2: Branded-generic launch

The applicant uses a differentiated name, packaging, multiple strengths and pharmacy support. This approach can preserve some margin without requiring a novel formulation, but it remains vulnerable to generic substitution and limited prescriber loyalty.

Scenario 3: Formulation-led launch

The applicant launches a taste-masked, orally disintegrating or modified-release product under an ANDA or 505(b)(2) strategy. The opportunity is larger, but so are development costs, patent requirements, bioequivalence risks and launch timing uncertainty.

Scenario 4: Combination-product launch

The applicant targets the phentermine/topiramate segment or another combination. This scenario requires a separate patent, regulatory and clinical assessment. Single-agent phentermine manufacturing capability is not sufficient.

Key Takeaways

• Phentermine’s core active-ingredient patent position is generally weak and does not create a substantial barrier to standard generic entry.
• The most practical generic opportunity is a conventional immediate-release tablet or capsule supported by low cost, reliable supply and strong controlled-substance compliance.
• Low-dose content uniformity is a central formulation and manufacturing risk.
• Taste masking, orally disintegrating delivery and extended release offer the clearest formulation-led differentiation.
• Qsymia and other combination products must be analyzed separately from single-agent phentermine.
• A current Orange Book review is required before relying on any patent or exclusivity conclusion for a specific reference product.
• FDA’s Inactive Ingredient Database can support excipient selection but does not replace product-specific formulation, stability and regulatory analysis.
• The commercial ceiling for ordinary phentermine is limited by generic competition and short-term labeling.
• The strongest premium opportunity is a technically differentiated dosage form with a defensible patent position and a clear patient-use advantage.

FAQs About Phentermine Excipients, Patents and Market Entry

Can microcrystalline cellulose be used in phentermine tablets?

Yes. Microcrystalline cellulose is a common oral tablet diluent and compression aid. Its suitability depends on the target strength, blend uniformity, dissolution profile and reference-product formulation.

Is phentermine suitable for an orally disintegrating tablet?

Yes, but taste masking is likely to be the main technical challenge. The product would also require control of friability, moisture sensitivity, disintegration time and packaging performance.

Does phentermine require a new patent for generic market entry?

No. A conventional generic applicant typically relies on an ANDA and does not need to obtain a new patent. A new patent becomes commercially useful when the applicant pursues a differentiated formulation or delivery system.

Can a company market phentermine for long-term weight management?

Marketing must remain consistent with the FDA-approved labeling. An applicant cannot create a chronic-use claim through excipient selection or packaging without appropriate regulatory support.

Is phentermine a biosimilar opportunity?

No. Phentermine is a small-molecule drug, not a biologic. The relevant pathways are generally ANDA or, for certain differentiated products, 505(b)(2), rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Phentermine hydrochloride prescribing information. FDA.

2. U.S. Drug Enforcement Administration. (2024). Controlled substance schedules. U.S. Department of Justice.

3. U.S. Food and Drug Administration. (2024). Adipex-P prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Lomaira prescribing information. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

6. U.S. Food and Drug Administration. (2024). Qsymia prescribing information. FDA.

7. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

8. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 314: Applications for FDA approval to market a new drug. U.S. Government Publishing Office.